Gilead-licensed experimental therapy reported eliminating woman’s cancer

Researchers at the U.S. National Cancer Institute grew copies of rare cells custom-made by the immune system from inside tumors and infused them back into a 49-year-old woman whose cancerous tumors were growing despite seven types of chemotherapy and hormonal therapy, reported Bloomberg. The experimental immune cell therapy, which has since been licensed to Gilead Sciences, left the woman cancer-free and also shrank hard-to-treat tumors in six other patients with colon and cervical cancers, according to a report about the study, the results of which were published Monday in the scientific journal Nature Medicine. In late morning trading, Gilead shares are up 1.6% to $69.42

https://bit.ly/2M0F4Ga